SPIRIT 3 - study to evaluate best use of TKIs in chronic phase CML

• Research type

  Research Study

• Full title

  A phase 3 randomised non-inferiority trial to evaluate the use of imatinib, nilotinib and ponatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia

• IRAS ID

  121308

• Contact name

  Stephen Gerard O'Brien

• Contact email

  stephen.o'brien@newcastle.ac.uk

• Sponsor organisation

  Newcastle upon Tyne Hospitals NHS Foundation Trust

• Eudract number

  2012-005696-14

• ISRCTN Number

  ISRCTN

• REC name

  London - Central Research Ethics Committee

• REC reference

  13/LO/1148

• Date of REC Opinion

  9 Sep 2013

• REC opinion

  Favourable Opinion